Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7334279

N=C(N)c1ccc2cc(C#CCNC(=O)c3ccc(N)cc3)ccc2c1.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ASIC3 Q9UHC3 1/20 0.46
PLAU P00749 12/20 0.45
SOST Q9BQB4 1/20 0.41
F10 P00742 4/20 0.40
PLG P00747 6/20 0.40
KLKB1 P03952 5/20 0.40
PRSS1 P07477 5/20 0.40
F2 P00734 5/20 0.40
PLAT P00750 4/20 0.40
KLK1 P06870 1/20 0.40
F7 P08709 1/20 0.37
F3 P13726 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
HIF1A Q16665 1/20 0.37
SLC22A6 Q4U2R8 1/20 0.37
SLC22A8 Q8TCC7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7336945 0.90 ASIC3 (0.46) ASIC3PLAUF10PLGKLKB1
Trifluoroacetic Acid SCHEMBL7353483 0.85 ASIC3 (0.64) ASIC3PLAUF10PLGKLKB1
Trifluoroacetic Acid SCHEMBL7334272 0.82 SOST (0.38) SOSTKDM4EMAPTHIF1ASLC22A6
Trifluoroacetic Acid SCHEMBL7334287 0.82 SOST (0.38) SOSTKDM4EMAPTHIF1ASLC22A6
Trifluoroacetic Acid SCHEMBL7337810 0.80 ASIC3 (0.51) ASIC3PLAUF10PLGKLKB1
SCHEMBL7335568 0.79 NOS3 (0.48) PLAUSOSTPLGKLKB1PRSS1
Trifluoroacetic Acid SCHEMBL7340242 0.78 ASIC3 (0.59) ASIC3PLAUPLGKLKB1PRSS1
SCHEMBL7334281 0.78 PLAU (0.45) ASIC3PLAUF10PLGKLKB1
Trifluoroacetic Acid SCHEMBL7335057 0.77 ASIC3 (0.79) ASIC3PLAUPLGKLKB1PRSS1
Trifluoroacetic Acid SCHEMBL7336009 0.76 ASIC3 (0.55) ASIC3PLAUF10PLGKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 ASIC3 4314/4885PLAU 2/4885SOST 1973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.